Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

[custom-facebook-feed id=Quanterix]

A recent @NatureMedicine publication recommends the use of Simoa p24 assay as a primary readout in clinical trials for HIV latency reversal treatments. Read more: https://go.nature.com/2Rydvbn #publicationalert #biomarkers

Quanterix is proud to sponsor ACTRIMS-ECTRIMS Congress 2020 kicking off today! Stop by our "virtual" booth to learn how we are powering ultra-sensitive biomarker detection with our Simoa technology. #MSvirtual2020

With the newly-released Neurology 2-plex B (Nf-L and GFAP), Quanterix is enabling testing to identify important ways to predict earlier disease or severity, monitor progression & quantify previously unmeasurable impact of drugs on neurological disorders. https://bit.ly/2FjPqCL

Joining #msvirtual2020 this weekend? Visit our virtual exhibit booth and experience the 40+ presentations using our Simoa technology to advance #MS diagnosis, monitoring and treatment. More details here: https://bwnews.pr/2DL5Hjd

This year’s #Walk2EndAlz won’t be a large in-person event, but Quanterix will still be walking and fundraising! Register now and walk on your own or with a small team of family and friends to fight Alzheimer’s:
https://bit.ly/35iUy4u. #ENDALZ

New study describes underlying processes that can produce toxic aggregates in patients with ALS and FTD, and suggests utility of plasma NfL in evaluating treatment efficacy https://bit.ly/2Z78wTa #research

Quanterix is pleased to be sponsoring this virtual meeting. Our own Paula Perin, Phd. will present on High Definition Simoa® Ultra-sensitive Cytokine Profiling for #COVID19 Research: Multiplexing with No Compromise on Sample Readability and Robustness @ESCVirology

Elsevier@IDAdvance

Do not miss the European Society for Clinical Virology’s free virtual meeting on COVID-19 taking place on 9 September 2020. Register now: https://bit.ly/31hksDq. @ESCVirology #COVID19 #ClinicalVirology

New #study in Nature Medicine identifies core peripheral blood immune signature in #COVID19 patients, which may help determine patient risk profile and provide insight on treatment options https://go.nature.com/32nHvvt

Quanterix CEO @KevinHrusovsky and @darragh_duffy discuss a new Simoa-powered study that suggests high-risk Covid-19 patients can be identified early via #biomarkers. Read more in @biospace. https://bit.ly/3iThECk #PPHSummit

Load More...

    Feed has no items.

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Quanterix Corporation

Building 1
900 Middlesex Turnpike
Billerica, MA 01821

+1 (617) 301-9400

www.quanterix.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account